Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Apexigen Completes $20 Million Series A Venture Round

publication date: Aug 6, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Apexigen, a California antibody company with strong connections to several China pharmas, raised $20 million in Series A1 financing. Apexigen was originally formed to be the drug development arm of Epitomics, a company built around a rabbit-based platform for developing monoclonal antibodies. Two China companies – Simcere and 3SBio – have filed with the CFDA to begin clinical trials of Apexigen-discovered drugs. More details....

Stock Symbols: (NYSE: SCR) (NSDQ: SSRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors